Detalles de la búsqueda
1.
BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension.
Epilepsia
; 58(7): 1217-1226, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28500678
2.
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Dement Geriatr Cogn Disord
; 33(5): 341-53, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22796905
3.
Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
CNS Neurosci Ther
; 22(6): 488-96, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27012596
4.
A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease.
Dement Geriatr Cogn Dis Extra
; 5(3): 361-74, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26557135
5.
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.
Alzheimers Res Ther
; 7(1): 9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25755685
6.
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Clin Neuropharmacol
; 37(1): 9-16, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24434526
7.
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Am J Alzheimers Dis Other Demen
; 28(6): 583-91, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23982674
Resultados
1 -
7
de 7
1
Próxima >
>>